Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Stoke Therapeutics, Inc. logoStoke Therapeutics, Inc.

STOK · Nasdaq · USD · Market cap $1.7B · 170 employees

Stoke Therapeutics, Inc.

FAIL · Does not pass the screen
26.81 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price26.81 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.13)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $35.00 to $53.38, base estimate $43.00 (screen dated 2026-11-20).

Current read
Accumulation ?
Undervalued · screened 2026-11-20
  • Trend Accumulation
  • Insiders insiders sold, $16,509, latest filing 2026-10-02
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.13, read 2026-11-19
  • Ethical does not pass the values gate
Price26.81 USD
Fair value43.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-10-26Read Accumulation25.68+4.4% to today ✓Markdown gives way to Accumulation after a 21% slide in 6 weeks
2026-09-14Read Markdown32.59-17.7% to today ✓Accumulation gives way to Markdown first Markdown read since July
2026-08-13Read Accumulation32.97-18.7% to today Markdown gives way to Accumulation after an 11% rise in 6 weeks
2026-07-02Read Markdown29.82-10.1% to today ✓First review on file: Markdown

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Stoke Therapeutics, Inc. holds its Accumulation at $26.81. Consolidating, no directional conviction, held for 1 days.

As held on the ledger · 2026-11-20
PhaseAccumulation
Quantitative stateConsolidating, no directional conviction, held for 1 days
Price at the screen$26.81
ValuationN/A trailing · -6.46 forward price to earnings
Values screenFAIL · score 70.0
Beta1.38
The Workings

Five Screens: STOK's Results

FAIL. Revenue purity

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 0.72% Below 33% Pass
Interest-bearing cash 25.39% Below 33% Pass
Receivables 21.55% Below 49% Pass
Revenue purity 7.46% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Stoke Therapeutics, clears the business-activity screen, and its debt is near-nil. Where it falls short is income purity: around 7% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when STOK's ethical verdict changes

Today STOK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 38% discount to our $43.00 fair value, 5.90% revenue growth.

Method.

35.00Conservative43.00Base case53.38Growth case 26.81Price

USD, 2026-11-20 screen. A 37.7% under base.

The Street's Range
35.00Street low 43.00Street average 60.00Street high 26.81Price

Street: 13 covering, consensus Strong Buy. Average target +60%.

Chart
The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-6.5x
EPS, trailing-3.81
EPS, forward-4.09
Revenue growth+5.9%slow but positive growth
Profit margin0.0%currently unprofitable
Return on equity-73.6%not currently earning a positive return on equity
FCF yield-7.27%
Debt to equity0.55moderate, manageable leverage
Current ratio7.24comfortably covers its short-term bills
Beta1.38moves a little more than the market
Short interest, float0.17%
52-week range22.05 - 40.22
Market cap$1.7B
Employees170

STOK-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Accumulation $26.69 +0.0% Entry 19
2026-11-19 Accumulation $26.69 -3.9% Entry 18

Since the last review it saw its composite score ease.

2026-11-12 Accumulation $27.76 +1.1% Entry 17
2026-11-05 Accumulation $27.45 +9.6% Entry 16

Since the last review it saw its composite score rise.

2026-10-29 Accumulation $25.04 -2.5% Entry 15
2026-10-28 Accumulation $25.68 +0.0% Entry 14
2026-10-27 Accumulation $25.68 +0.0% Entry 13
2026-10-26 Accumulation · changed $25.68 +0.0% Entry 12

The framework has shifted from markdown to accumulation since the last review.

2026-10-25 Markdown $25.68 +0.0% Entry 11
2026-10-24 Markdown $25.68 +0.0% Entry 10

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on STOK

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in STOK's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · STOK
DateInsiderTitleTypeSharesValue
2026-10-02 Allan Jonathan GC, Corp Sec S - Sale 627 $16,509
2026-10-01 Ticho Barry Chief Medical Officer S - Sale 1,051 $27,494

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $32.64 -12.8% · $873 -12.8%
2 months $34.33 -17.0% · $830 -17.0%
3 months $36.48 -21.9% · $781 -21.9%
6 months $33.09 -13.9% · $861 -13.9%
1 year $11.36 +150.7% · $2,507 +150.7%
2 years $14.89 +91.3% · $1,913 +91.3%
3 years $11.76 +142.2% · $2,422 +142.2%
5 years $37.71 -24.5% · $755 -24.5%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever STOK does next, these words stay.

Stoke Therapeutics, Inc. · STOK · Accumulation · $26.81
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.